These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 20738248)

  • 1. Insights into the molecular mechanism of hERG1 channel activation and blockade by drugs.
    Durdagi S; Subbotina J; Lees-Miller J; Guo J; Duff HJ; Noskov SY
    Curr Med Chem; 2010; 17(30):3514-32. PubMed ID: 20738248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined receptor and ligand-based approach to the universal pharmacophore model development for studies of drug blockade to the hERG1 pore domain.
    Durdagi S; Duff HJ; Noskov SY
    J Chem Inf Model; 2011 Feb; 51(2):463-74. PubMed ID: 21241063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cardiac hERG/IKr potassium channel as pharmacological target: structure, function, regulation, and clinical applications.
    Thomas D; Karle CA; Kiehn J
    Curr Pharm Des; 2006; 12(18):2271-83. PubMed ID: 16787254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In silico prediction of the chemical block of human ether-a-go-go-related gene (hERG) K+ current.
    Inanobe A; Kamiya N; Murakami S; Fukunishi Y; Nakamura H; Kurachi Y
    J Physiol Sci; 2008 Dec; 58(7):459-70. PubMed ID: 19032804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [HERG K+ channel, the target of anti-arrhythmias drugs].
    Guan FY; Yang SJ
    Yao Xue Xue Bao; 2007 Jul; 42(7):687-91. PubMed ID: 17882949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular determinants of cocaine block of human ether-รก-go-go-related gene potassium channels.
    Guo J; Gang H; Zhang S
    J Pharmacol Exp Ther; 2006 May; 317(2):865-74. PubMed ID: 16397089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Revealing the structural basis of action of hERG potassium channel activators and blockers.
    Perry M; Sanguinetti M; Mitcheson J
    J Physiol; 2010 Sep; 588(Pt 17):3157-67. PubMed ID: 20643767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In silico prediction of hERG inhibition.
    Jing Y; Easter A; Peters D; Kim N; Enyedy IJ
    Future Med Chem; 2015; 7(5):571-86. PubMed ID: 25921399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure driven design of novel human ether-a-go-go-related-gene channel (hERG1) activators.
    Guo J; Durdagi S; Changalov M; Perissinotti LL; Hargreaves JM; Back TG; Noskov SY; Duff HJ
    PLoS One; 2014; 9(9):e105553. PubMed ID: 25191697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-118057 contacts the pore helix of hERG1 channels to attenuate inactivation and enhance K+ conductance.
    Perry M; Sachse FB; Abbruzzese J; Sanguinetti MC
    Proc Natl Acad Sci U S A; 2009 Nov; 106(47):20075-80. PubMed ID: 19892732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel structure-based virtual screening model for the hERG channel blockers.
    Du L; Li M; You Q; Xia L
    Biochem Biophys Res Commun; 2007 Apr; 355(4):889-94. PubMed ID: 17331468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modeling of the hERG K+ Channel Blockage Using Online Chemical Database and Modeling Environment (OCHEM).
    Li X; Zhang Y; Li H; Zhao Y
    Mol Inform; 2017 Dec; 36(12):. PubMed ID: 28857516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human ether-a-go-go-related gene channel blockers and its structural analysis for drug design.
    Narayana Moorthy NS; Ramos MJ; Fernandes PA
    Curr Drug Targets; 2013 Jan; 14(1):102-13. PubMed ID: 23061466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Computational investigations of hERG channel blockers: New insights and current predictive models.
    Villoutreix BO; Taboureau O
    Adv Drug Deliv Rev; 2015 Jun; 86():72-82. PubMed ID: 25770776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The hERG potassium channel as a therapeutic target.
    Witchel HJ
    Expert Opin Ther Targets; 2007 Mar; 11(3):321-36. PubMed ID: 17298291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Propofol inhibits hERG K
    Han SN; Jing Y; Yang LL; Zhang Z; Zhang LR
    Eur J Pharmacol; 2016 Nov; 791():168-178. PubMed ID: 27575519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug block of the hERG potassium channel: insight from modeling.
    Stansfeld PJ; Gedeck P; Gosling M; Cox B; Mitcheson JS; Sutcliffe MJ
    Proteins; 2007 Aug; 68(2):568-80. PubMed ID: 17444521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Pore-Lipid Interface: Role of Amino-Acid Determinants of Lipophilic Access by Ivabradine to the hERG1 Pore Domain.
    Perissinotti L; Guo J; Kudaibergenova M; Lees-Miller J; Ol'khovich M; Sharapova A; Perlovich GL; Muruve DA; Gerull B; Noskov SY; Duff HJ
    Mol Pharmacol; 2019 Aug; 96(2):259-271. PubMed ID: 31182542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combining structure- and ligand-based approaches for studies of interactions between different conformations of the hERG K+ channel pore and known ligands.
    Coi A; Bianucci AM
    J Mol Graph Model; 2013 Nov; 46():93-104. PubMed ID: 24185260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ivabradine prolongs phase 3 of cardiac repolarization and blocks the hERG1 (KCNH2) current over a concentration-range overlapping with that required to block HCN4.
    Lees-Miller JP; Guo J; Wang Y; Perissinotti LL; Noskov SY; Duff HJ
    J Mol Cell Cardiol; 2015 Aug; 85():71-8. PubMed ID: 25986146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.